QIAGEN can use Ares Genetics’ Antimicrobial Resistance (AMR) database and use its expertise in bioinformatics to accelerate AMR research.

QIAGEN N.V., the Netherlands-based provider of Sample to Insight solutions recently announced that it has signed a broad agreement with Ares Genetics that specializes in infectious disease diagnostics and therapeutics, to accelerate research related to antibiotic-resistant bacteria by developing innovative bioinformatics and assay solutions.

QIAGEN reportedly acquired an exclusive license to use ARESdb, proprietary antimicrobial resistance database developed by Ares Genetics, as well as to leverage AREStools, the ARES Technology Platform from which it will utilize workflows and bioinformatics tools, in its bioinformatics products and services for researchers. QIAGEN also acquired a non-exclusive global license to use ARESdb content to develop and commercialize molecular research assays in collaboration with its polymerase chain reaction (PCR) and next-generation sequencing (NGS) solutions.

Sources close to the matter state that artificial intelligence powered ARESdb is possibly the most comprehensive and updated proprietary knowledge base related to genetic antibiotic resistance markers.

Dr. Andreas Posch, CEO and MD of Ares Genetics has been reported to say that ARESdb can become a key resource for cutting-edge research in antimicrobial resistance through this agreement with QIAGEN which will become a prime supplier of applications for the analysis and interpretation of biological data.

He added that the partnership can greatly facilitate Ares’ engagement with the public health and research communities in further boosting and expanding ARESdb, a database that is also integral to the NGS-based diagnostic solutions presently being developed by Ares Genetics.

Jonathan Sheldon, Senior VP and head of QIAGEN Bioinformatics has been quoted to say that QIAGEN is a leader in providing Sample to Insight solutions that can combat the antibiotic-resistant diseases crisis being faced by global public health sector. The collaboration with ARES will help in expanding the portfolio for infectious disease research tools. He added that QIAGEN can benefit from the use of the Antimicrobial resistance (AMR) database developed by Ares Genetics and with its expertise in bioinformatics can enable the research community to accelerate the battle against AMR.

Financial details of the partnership were not disclosed